The R0 resection rate after neoadjuvant bevacizumab (Bev) plus DOF versus DOF in local advanced gastric carcinoma (LAGC) and its association with circulating tumor cell (CTC).
Nan Du
No relevant relationships to disclose
Junxun Ma
No relevant relationships to disclose
Shan Wang
No relevant relationships to disclose
Xiaosong Li
No relevant relationships to disclose
Junzhong Sun
No relevant relationships to disclose
Huanrong Kang
No relevant relationships to disclose
Yan Fu
No relevant relationships to disclose
Hui Zhao
No relevant relationships to disclose
Yi Hu
No relevant relationships to disclose